Sharon B. Murphy

TL;DR: Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.

TL;DR: It is concluded that there is a substantial risk of AML in patients who receive intensive treatment for ALL, especially in those with a T-cell immunophenotype, and that 11q23 chromosomal abnormalities may be important in the pathogenesis of this complication.

TL;DR: Outcome within risk groups was not significantly affected by the speed of rotation of drug pairs during continuation treatment, and various high-risk subgroups had apparently improved responses to this treatment.

TL;DR: The activities of the National Cancer Policy Forum workshop are reviewed, which examined the elements of a rapid-learning system for cancer, including registries and databases, emerging information technology, patient-centered and -driven clinical decision support, patient engagement, culture change, clinical practice guidelines, and federal policy issues and implications.

TL;DR: It is concluded that when added to a backbone of effective rotating agents, repeated doses of asparaginase during early treatment improve the outcome for patients with T cell leukemia and advanced stage lymphoblastic lymphoma.